trophy. N Engl J Med 1995；333：288‒293. 9） Eng CM, Guffon N, Wilcox WR, et al：Safety and effica-cy of recombinant human alpha‒galactosidase A‒replace-ment therapy in Fabry’s disease. N Engl J Med 2001；345：9‒16. 10） Schiffmann R, Kopp JB, Austin HA 3rd, et al：Enzyme replacement therapy in Fabry disease：a randomized con-trolled trial. JAMA 2001；285：2743‒2749. 11） Germain DP, Charrow J, Desnick RJ, et al：Ten‒year out-come of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015；52：353‒358. 12） Juan P, Hernan A, Beatriz SA, et al：Fabry Disease：Mul-tidisciplinary Evaluation After 10 Years of Treatment with Agalsidase Beta. JIMD Rep 2014；16：7‒14. 13） Beck M, Hughes D, Kampmann C, et al：Long‒term effectiveness of agalsidase alfa enzyme replacement in Fabry disease：A Fabry Outcome Survey analysis. Mol Genet Metab Rep 2015；3：21‒27. 14） Schiffmann R, Goker‒Alpan O, Holida M, et al：Peguni-galsidase alfa, a novel PEGylated enzyme replacement-therapy for Fabry disease, provides sustained plasmacon-centrations and favorable pharmacodynamics：A 1‒year-Phase 1/2 clinical trial. J Inherit Metab Dis 2019；42：534‒544. 15） Guérard N, Oder D, Nordbeck P, et al：Lucerastat, an Imi-nosugar for Substrate Reduction Therapy：Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement. Clin Phar-macol Ther 2018；103：703‒711. 16） Felis A, Whitlow M, Kraus A, et al：Current and Investi-gational Therapeutics for Fabry Disease. Kidney Int Rep 2020；5：407‒413. 17） Khan A, Barber DL, Huang J, et al：Lentivirus‒mediated gene therapy for Fabry disease. Nat Commun 2021；12：1178‒1283. 18） Yasuda M, Huston MW, Pagant S, et al：AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Sub-strate Reduction. Mol Ther Methods Clin Dev 2020；18：607‒619. 19） Kevany BM, Kerns S, Padegimas L, et al：AAV gene therapy for the treatment of Fabry disease：A novel cap-sid with improved tropism to heart, kidney and CNS and improved GLA expression. Mol Genet Metab 2019；126：83. 20） Spada M, Pagliardini S, Yasuda M, et al：High incidence of later‒onset fabry disease revealed by newborn screen-ing. Am J Hum Genet 2006；79：31‒40. 21） Chien YH, Lee NC, Chiang SC, et al：Fabry disease：incidence of the common later‒onset α‒galactosidase A IVS4＋919 G→A mutation in Taiwanese newborns‒‒superiority of DNA‒based to enzyme‒based newborn screening for common mutations. Mol Med 2012；18：780‒784. 22） Sawada T, Kido J, Yoshida S, et al：Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep 2020；22：100562. 23） Inoue T, Hattori K, Ihara K, et al：Newborn screening for Fabry disease in Japan：prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 2013；58：548‒552. 24） de Duve C：The lysosome turns fifty. Nat Cell Biol 2005；7：847‒849. 25） Ballabio A, Bonifacino JS：Lysosomes as dynamic regu-lators of cell and organismal homeostasis. Nat Rev Mol Cell Bio 2020；21：101‒118. 26） Ballabio A：The awesome lysosome. EMBO Mol Med 2016；8：73‒76. 27） Eckhardt M：Pathology and current treatment of neurode-generative sphingolipidoses. Neuromolecular Med 2010；12：362‒382. 28） Miyatake T：A study on glycolipids in Fabry’s disease. Jpn J Exp Med 1969；39：35‒45. 29） Lou HO：A biochemical investigation of angiokeratoma corporis diffusum. Acta Pathol Microbiol Scand 1966；68：332‒342. 30） Ballabio A, Gieselmann V：Lysosomal disorders：from storage to cellular damage. Biochim Biophys Acta 2009；1793：684‒696. 31） Bishop DF, Desnick RJ：Affinity purification of α‒galac-tosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms. J Biol Chem 1981；256：1307‒1316. 32） Bishop DE, Sweeley CC：Plasma α‒galactosidase A：properties and comparisons with tissue α‒galactosidase. Biochim Biophys Acta 1978；525：399‒409. 33） Ioannou YA, Zeidner KM, Grace ME, et al：Human α‒galactosidase A：glycosylation site 3 is essential for enzyme solubility. Biochem J 1998；332：789‒797. 34） Eng CM, Fletcher J, Wilcox WR, et al：Fabry disease：baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007；30：184‒192. 35） Germain DP, Waldek S, Banikazemi M, et al：Sustained, long‒term renal stabilization after 54 months of agalsi-dase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007；18：1547‒1557. 36） Warnock D, Mauer M：Fabry disease：dose matters. J Am Soc Nephrol 2014；25：653‒655. 37） Rombach SM, Smid BE, Bouwman MG, et al：Long term enzyme replacement therapy for Fabry disease：effec-tiveness on kidney, heart and brain. Orphanet J Rare Dis 2013；8：47‒56.91 ファブリー病の歴史と概要
元のページ ../index.html#9